Societal CDMO, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2021-11-12: Form 8-K; Period of report 2021-11-12; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2021-11-09: Form 8-K; Period of report 2021-11-09; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2021-09-10: Form 8-K/A; Period of report 2021-08-10; Description 8.01 Other Events; Details 8.01.
- 2021-08-23: Form 8-K; Period of report 2021-08-23; Description 7.01 Regulation FD Disclosure; Details 7.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2021-11-12 | 8-K | 2021-11-12 | 7.01 Regulation FD Disclosure | 7.01 Attached as Exhibit 99.1 and furnished for purposes of Regulation FD is a presentation that the Company will post on its website on November 12, 2021 and may use from time to time in presentations or discussions with investors, analysts, and other parties. | reph-20211112.htm |
| 2021-11-09 | 8-K | 2021-11-09 | 2.02 Results of Operations and Financial Condition | 2.02 On November 9, 2021, Recro Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2021. | reph-20211109.htm |
| 2021-09-10 | 8-K/A | 2021-08-10 | 8.01 Other Events | 8.01 The acquisition and integration of IriSys may present many risks and we may not realize the strategic and financial goals that were contemplated at the time we entered into the Purchase Agreement. | reph-20210810.htm |
| 2021-08-23 | 8-K | 2021-08-23 | 7.01 Regulation FD Disclosure | 7.01 Attached as Exhibit 99.1 and furnished for purposes of Regulation FD is a presentation that the Company will post on its website on August 23, 2021 and may use from time to time in presentations or discussions with investors, analysts, and other parties. | reph-20210823.htm |
| 2021-08-19 | 8-K | 2021-08-17 | 7.01 Regulation FD Disclosure | 7.01 On August 17, 2021, Recro Pharma, Inc. (the “Company”) issued a press release announcing a webcast to discuss the Company’s recent acquisition of IRISYS, LLC to be held on August 19, 2021 at 11:00 am EDT (the "Webcast"). | reph-20210817.htm |
| 2021-08-13 | 8-K | 2021-08-10 | 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 2.01 Reference is made to the disclosure under Item 1.01 above which is hereby incorporated in this Item 2.01 by reference. 2.03 Reference is made to the disclosure under Item 1.01 above which is hereby incorporated in this Item 2.03 by reference. 3.02 Reference is made to the disclosure under Item 1.01 above which is hereby incorporated in this Item 3.02 by reference. 7.01 On August 10, 2021, the Company issued a press release announcing its entrance into a letter of intent in connection with the Acquisition. | reph-20210810.htm |
| 2021-08-09 | 8-K | 2021-08-09 | 2.02 Results of Operations and Financial Condition | 2.02 On August 9, 2021, Recro Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended June 30, 2021. | reph-20210809.htm |
| 2021-06-16 | 8-K | 2021-06-14 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On June 14, 2021, the Board of Directors (the “Board”) of Recro Pharma, Inc. (the “Company”) appointed Laura L. Parks, Ph.D. to serve as a Class III member of the Board. | reph-20210614.htm |
| 2021-06-01 | 8-K | 2021-06-01 | 7.01 Regulation FD Disclosure | 7.01 Attached as Exhibit 99.1 and furnished for purposes of Regulation FD is a presentation that the Company will post on its website on June 1, 2021 and may use from time to time in presentations or discussions with investors, analysts, and other parties. | reph-20210601.htm |
| 2021-05-13 | 8-K | 2021-05-12 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d139813d8k.htm |
| 2021-05-11 | 8-K | 2021-05-11 | 8.01 Other Events | 8.01 On May 11, 2021, Recro Pharma, Inc. (the “Company”) updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | reph-20210511.htm |
| 2021-05-06 | 8-K | 2021-05-06 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On May 6, 2021, Recro Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2021. 7.01 Attached as Exhibit 99.2 and furnished for purposes of Regulation FD is a presentation that the Company will post on its website on May 6, 2021 and may use from time to time in presentations or discussions with investors, analysts, and other parties. | reph-20210506.htm |
| 2021-04-21 | 8-K | 2021-04-20 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On April 20, 2021, Recro Pharma, Inc. (the “Company”) held its Annual Meeting of Shareholders (the “Annual Meeting”). | reph-20210420.htm |
| 2021-04-20 | 8-K | 2021-04-20 | 7.01 Regulation FD Disclosure | 7.01 Attached as Exhibit 99.1 and furnished for purposes of Regulation FD is a presentation that the Company will deliver during its 2021 Annual Meeting of Shareholders and may use from time to time in presentations or discussions with investors, analysts, and other parties. | reph-8k_20210420.htm |
| 2021-02-26 | 8-K | 2021-02-26 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On February 26, 2021, Recro Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2020. 7.01 Attached as Exhibit 99.2 and furnished for purposes of Regulation FD is a presentation that the Company will post on its website on February 26, 2021 and may use from time to time in presentations or discussions with investors, analysts, and other parties. | reph-8k_20210226.htm |
| 2021-02-26 | 8-K | 2021-02-26 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d480193d8k.htm |
| 2021-02-23 | 8-K | 2021-02-19 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 3.02 The information in Item 1.01 above is incorporated in this Item 3.02 by reference. | d114387d8k.htm |
| 2021-02-16 | 8-K | 2021-02-09 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 9, 2021, the Board of Directors (the “Board”) of Recro Pharma, Inc. (the “Company”) appointed James C. Miller to serve as a Class I member of the Board. | d96205d8k.htm |
| 2021-01-14 | 8-K | 2021-01-08 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 8, 2021, the Compensation Committee (the “Committee”) of the Board of Directors of Recro Pharma, Inc. (the “Company”) approved equity grants to Ryan D. Lake, Chief Financial Officer of the Company, as compensation for his service in 2020. | d13895d8k.htm |